Zusammenfassung
DieTherapie tachykarder Rhythmusstörungen wurde in den vergangen 10 Jahren revolutioniert. Der Stellenwert der medikamentösen antiarrhythmischen Therapie hat stark abgenommen, nachdem die CAST-Studie (Cardiac Arrhythmia Suppression Trial Investigators 1989) eine Übersterblichkeit von Patienten mit ventrikulären Arrhythmien nach Myokardinfarkt unter Klasse-I-Antiarrhythmika gezeigt hatte. Dank der rasanten technologischen Entwicklung sind maligne ventrikuläre Arrhythmien zur Domäne des implantierbaren Defibrillators geworden (The Antiarrhythmics versus Implantable Defibrillators [AVID] Investigators 1997). Regelmäßige supraventrikuläre Tachykardien können mit hoher Erfolgsrate durch die Radiofrequenz-Katheterablation kurativ behandelt werden. Die Therapie des weit verbreiteten Vorhofflimmerns bleibt im Wesentlichen eine medikamentöse, wobei erste interventionelle Verfahren für die Zukunft auf kurative Ansätze hoffen lassen (Haissaguerre et al. 2000).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G (1999) A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341: 1882–1890
Cairns JA et al. (1997) Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations:CAMIAT. Lancet 349:675
Capucci A et al. (1994) Conversion of recent onset atrial fibrillation to sinus rhythm by a single oral loading dose of propafenone or flecainide. Am J Cardiol 74:503
Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406
Dorian P, Cass D, Schwartz B et al. (2002) Amiodarone as compared to with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346:884–890
Fetsch T, Breithardt G, Engberding R et al. (2001) Prevention of atrial fibrillation after cardioversion — results from the PAFAC trial. Circulation 104 (Suppl II):699 (Abstract)
Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG, on behalf of the Stroke Prevention in Atrial Fibrillation Investigators (1992) Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 20:527
Fuster V et al. (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Circulation 104:2118–2150
Haissaguerre M, Jais P, Shah D et al. (2000) Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 101:1409–1417
Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Rinkenberger RL, Zipes DP (1981) Amiodarone — clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305:539
Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation — Pharmacological Intervention in Atrial Fibrillation (PIAF):a randomized trial. Lancet 356:1789–1794
Jackman WM, Wang X, Friday KJ, Roman CA et al. (1991) Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 324: 1605.
Jackman WM, Beckman KJ, McClelland JH et al. (1992) Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow pathway conduction. N Engl J Med 327:313
Julian DG et al. (1997) Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349:667
Klein AL, Grimm RA, Murray RD et al. (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344:1411–1420
Lüderitz B (1998) Therapie der Herzrhythmusstörungen, 5. Aufl. Springer, Berlin Heidelberg New York Tokyo
Meinertz T, Hofmann T, Kasper W, Treese N, Bechtold H, Stienen U, Pop T, von Leitner ER, Andresen D, Meyer J (1984) Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 53:902
MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007
Morady F, Sauve MJ, Malone P, Shen EN, Schwartz AB, Bhzandari A, Keung E, Sung RJ, Scheinman MM (1983) Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 52:975
Moss AJ et al. (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335:1933
Moss AJ et al. (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883
Multicenter Postinfarction Research Group (1983) Risk stratification and survival after myocardial infarction. N Engl J Med 309:331
Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B (1989) Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation:the Copenhagen AFASAK Study. Lancet 1:175
Reithmann C, Hoffmann E, Spitzlberger G et al. (2000) Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. Eur Heart J 21:565–572
SPAF II: The Stroke Prevention in Atrial Fibrillation Investigators (1994) Warfarin vs. aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687
Steinbeck G (1983) Tachykarde Rhythmusstörungen. In: Lüderitz B (Hrsg) Handbuch der inneren Medizin. Bd IX/1: Herzrhythmusstörungen. Springer, Berlin Heidelberg New York Tokyo, S 617
Steinbeck G, Andresen D, Bach P et al. (1992) A comparison of electro-physiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med 327:987
Stoddard MF et al. (1995) Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transoesophageal echocardiography study. J Am Coll Cardiol 25:452
The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576
The Cardiac Insufficiency Bisoprolol Stuby II (CIBIS-II): a randomized trial (1999) Lancet 353:9–131
Vaughan-Williams EM (1970) Classification of antiarrhythmic drugs. In:Sandoe E, Flenstedt-Jensen E, Olesen KH (eds) Symposium on cardiac arrhythmias. Astra, Södertälje/Sweden,p 449
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Steinbeck, G., Dorwarth, U. (2003). Tachykarde Rhythmusstörungen. In: Therapie innerer Krankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10475-0_12
Download citation
DOI: https://doi.org/10.1007/978-3-662-10475-0_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-10476-7
Online ISBN: 978-3-662-10475-0
eBook Packages: Springer Book Archive